H.C. Wainwright Sticks to Its Hold Rating for Aeglea Biotherapeutics (AGLE)

In a report released today, Edward White from H.C. Wainwright reiterated a Hold rating on Aeglea Biotherapeutics (AGLEResearch Report), with a price target of $1.00. The company’s shares closed yesterday at $1.14.

According to TipRanks, White is an analyst with an average return of -25.8% and a 22.35% success rate. White covers the Healthcare sector, focusing on stocks such as TRACON Pharmaceuticals, Aeglea Biotherapeutics, and Valneva.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aeglea Biotherapeutics with a $1.88 average price target.

See Insiders’ Hot Stocks on TipRanks >>

AGLE market cap is currently $70.12M and has a P/E ratio of -0.91.

Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGLE in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Read More on AGLE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More